
Intranasal Multiepitope PD-L1-siRNA-based Nanovaccine: The Next-Gen COVID-19 Immunotherapy
Discover the future of COVID-19 immunotherapy with the innovative intranasal multiepitope PD-L1-siRNA-based nanovaccine. Explore the cutting-edge technology, nanotechnology elements, and futuristic nasal spray device in this sleek and scientific image.
- Creations
- 7
- Images
- 28
- Model
- turbo
- Likes
- 0
- 1 / 7turbo1:1
cover for article with this title: Intranasal Multiepitope PD-L1-siRNA-based Nanovaccine: The Next-Gen COVID-19 immunotherapy
- 2 / 7turbo1:1
novel intranasal nano vaccine with siRNA
- 3 / 7turbo1:1
novel intranasal multiepitop Dendritic cells targeted nano-vaccine against COVID-19
- 4 / 7turbo1:1
novel intranasal administration of multiepitop nano-vaccine against COVID-19. Stable in room temperature and relevant to the treatment of third-world countries.
- 5 / 7turbo1:1
novel intranasal administration of multiepitop nano-vaccine against COVID-19. Stable at room temperature and relevant to the treatment of third-world countries. Make it friendly and sophisticated
- 6 / 7turbo1:1
A plug and play nano-system: novel intranasal administration of multiepitop nano-vaccine against COVID-19. Stable at room temperature and relevant to the treatment of third-world countries. Make it friendly and sophisticated
- 7 / 7turbo1:1
A plug and play nano-system: novel multiepitop nano-vaccine against COVID-19. Make it friendly and sophisticated
Related posters & design
More like this from the community.












































